Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | PTPRB | P23467 | 2/20 | 0.40 |
| ▸ | GLP1R | P43220 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | GHSR | Q92847 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10248929 | 0.78 | SLC6A3 (0.43) | SLC6A3PTPRBDRD2HTR2AHRH1 | |
| SCHEMBL16018753 | 0.78 | SLC6A3 (0.43) | SLC6A3PTPRBDRD2HTR2AHRH1 | |
| SCHEMBL10249190 | 0.78 | SLC6A3 (0.56) | SLC6A3PTPRBDRD2HTR2AHRH1 | |
| SCHEMBL10252493 | 0.76 | LTA4H (0.48) | SLC6A3NPC1ALDH1A1GAARAB9A | |
| SCHEMBL13604293 | 0.76 | CYP17A1 (0.44) | SLC6A3DRD2HTR2AHRH1NPC1 | |
| SCHEMBL10094544 | 0.76 | RAB9A (0.45) | PTGS2ALDH1A1RAB9A | |
| SCHEMBL10252529 | 0.75 | LTA4H (0.47) | SLC6A3PTPRBDRD2HTR2AHRH1 | |
| SCHEMBL10248949 | 0.75 | LOXL2 (0.42) | SLC6A3PTPRBDRD2HTR2AHRH1 | |
| SCHEMBL7187338 | 0.71 | SLC6A3 (0.43) | SLC6A3PTPRBDRD2HTR2AHRH1 | |
| SCHEMBL13231429 | 0.71 | ENPP2 (0.54) | PTGS2NPC1ALDH1A1GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124610-B2 | Sodium channel inhibitors | ICAGEN INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090023740-A1 | SODIUM CHANNEL INHIBITORS | ICAGEN (US) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023740-A1 | SODIUM CHANNEL INHIBITORS | TRPV1, SCN1A, SCN2A | SLC6A3 227/4885PTPRB 545/4885GLP1R 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.